David F.  Hale net worth and biography

David Hale Biography and Net Worth

Director of Biocept
Mr. Hale is the Chairman and CEO of Hale BioPharma Ventures LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. Mr. Hale is a serial entrepreneur who has been involved in the founding and/or development of a number of life sciences technology companies and is currently the Chairman of Oncternal Pharmaceuticals and served as Chairman of our board at Biocept until 2020. He was previously President and CEO of CancerVax Corporation, a cancer therapeutic company from October 2000 through May 2006 when CancerVax merged with Micromet, Inc. He became Chairman of Micromet, Inc. until the sale of the company to Amgen Inc. in 2012. After joining Hybritech, Inc., in 1982, he was President & Chief Operating Officer and became CEO in 1986, when Hybritech was acquired by Eli Lilly and Co. From 1987 to 1997 he was Chairman, President and CEO of Gensia, Inc. He was a co-founder and Chairman of Viagene, Inc. from 1987 to 1995. He was President and CEO of Women First HealthCare, Inc. from January 1998 to June 2000. Prior to joining Hybritech in 1982, Mr. Hale was Vice President and General Manager of BBL Microbiology Systems, a division of Becton, Dickinson & Co. and from 1971 to 1980, held various marketing and sales management positions with Ortho Pharmaceutical Corporation, a division of Johnson & Johnson, Inc.

Mr. Hale previously served as Chairman of Santarus, Inc., Somaxon, Inc., SkinMedica, Inc., CRISIMed, Inc. and Agility Clinical, Inc. He also serves as Chairman of a number of privately held companies, including MDR Aesthetics Inc., Recros Medica, Inc., Clarify Medical, Inc., Neurana Pharmaceuticals, Inc. and Adigica Health, Inc., and as a Director of Neurelis, Inc.

Mr. Hale also is a co-founder and serves on the Board of Directors of BIOCOM, is a former member of the board of Biotechnology Industry Organization, or BIO, and the Biotechnology Institute. Mr. Hale also serves as a member of the board of directors of the San Diego Economic Development Corporation, as a board trustee of Rady Children’s Hospital of San Diego, Chairman of the board of Rady Children’s Institute of Pediatric Genomics and a trustee of the Salk Institute. He is a co-founder of the CONNECT Program in Technology and Entrepreneurship. Mr. Hale holds a B.A. in Biology and Chemistry from Jacksonville State University.

What is David F. Hale's net worth?

The estimated net worth of David F. Hale is at least $0.00 as of February 23rd, 2024. Mr. Hale owns 714 shares of Biocept stock worth more than $0 as of April 20th. This net worth approximation does not reflect any other investments that Mr. Hale may own. Learn More about David F. Hale's net worth.

How do I contact David F. Hale?

The corporate mailing address for Mr. Hale and other Biocept executives is 5810 Nancy Ridge Drive, San Diego CA, 92121. Biocept can also be reached via phone at (858) 320-8200 and via email at [email protected]. Learn More on David F. Hale's contact information.

Has David F. Hale been buying or selling shares of Biocept?

David F. Hale has not been actively trading shares of Biocept within the last three months. Most recently, David F. Hale sold 2 shares of the business's stock in a transaction on Thursday, December 9th. The shares were sold at an average price of $122.10, for a transaction totalling $244.20. Learn More on David F. Hale's trading history.

David F. Hale Insider Trading History at Biocept

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/9/2021Sell2$122.10$244.20View SEC Filing Icon  
6/12/2020Sell38$16.50$627.00View SEC Filing Icon  
10/19/2016Buy3,030$33.00$99,990.00View SEC Filing Icon  
2/13/2015Buy1,333$37.50$49,987.50View SEC Filing Icon  
See Full Table

David F. Hale Buying and Selling Activity at Biocept

This chart shows David F Hale's buying and selling at Biocept by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Biocept Company Overview

Biocept logo
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.97
Low: $0.43
High: $1.67

2 Week Range

Now: N/A

Volume

751,400 shs

Average Volume

764,067 shs

Market Capitalization

$1.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69